http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2025, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Sun, 05 Oct 2025 20:00:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Hot+List/UBS+on+why+it%27s+still+not+ready+to+push+the+buy+button+on+pharma+stocks/25420510.html <p>There are many factors that appear supportive for Pharma heading into Q3. And yet, UBS says it is not yet ready to turn bullish on the sector, though it has highlighted several stocks it has Buy ratings on.</p><p>Among the factors that appear positive for benchmark Pharma is UBS’s GDP forecasts, according to which PMIs should fall. Pharma is the most negatively correlated sector with PMIs, points out UBS. Also, it is discounting a PMI of 60, where its underperformance is consistent with a European GDP growth rate of +3%.</p><p>Also, notes UBS, Pharma typically underperforms when credit spreads rise, given its http://www.streetinsider.com/Hot+List/UBS+on+why+it%27s+still+not+ready+to+push+the+buy+button+on+pharma+stocks/25420510.html Sun, 05 Oct 2025 20:00:00 -0400 ABT IHE JNJ http://www.streetinsider.com/Hot+List/UBS+on+why+it%27s+still+not+ready+to+push+the+buy+button+on+pharma+stocks/25420510.html <p>There are many factors that appear supportive for Pharma heading into Q3. And yet, UBS says it is not yet ready to turn bullish on the sector, though it has highlighted several stocks it has Buy ratings on.</p><p>Among the factors that appear positive for benchmark Pharma is UBS’s GDP forecasts, according to which PMIs should fall. Pharma is the most negatively correlated sector with PMIs, points out UBS. Also, it is discounting a PMI of 60, where its underperformance is consistent with a European GDP growth rate of +3%.</p><p>Also, notes UBS, Pharma typically underperforms when credit spreads rise, given its http://www.streetinsider.com/Hot+List/UBS+on+why+it%27s+still+not+ready+to+push+the+buy+button+on+pharma+stocks/25420510.html Sun, 05 Oct 2025 20:00:00 -0400 ABT IHE JNJ http://www.streetinsider.com/Hot+List/UBS+on+why+it%27s+still+not+ready+to+push+the+buy+button+on+pharma+stocks/25420510.html <p>There are many factors that appear supportive for Pharma heading into Q3. And yet, UBS says it is not yet ready to turn bullish on the sector, though it has highlighted several stocks it has Buy ratings on.</p><p>Among the factors that appear positive for benchmark Pharma is UBS’s GDP forecasts, according to which PMIs should fall. Pharma is the most negatively correlated sector with PMIs, points out UBS. Also, it is discounting a PMI of 60, where its underperformance is consistent with a European GDP growth rate of +3%.</p><p>Also, notes UBS, Pharma typically underperforms when credit spreads rise, given its http://www.streetinsider.com/Hot+List/UBS+on+why+it%27s+still+not+ready+to+push+the+buy+button+on+pharma+stocks/25420510.html Sun, 05 Oct 2025 20:00:00 -0400 ABT IHE JNJ http://www.streetinsider.com/Hot+List+Pro/UBS+on+why+it%27s+still+not+ready+to+push+the+buy+button+on+pharma+stocks/25420510.html <p>There are many factors that appear supportive for Pharma heading into Q3. And yet, UBS says it is not yet ready to turn bullish on the sector, though it has highlighted several stocks it has Buy ratings on.</p><p>Among the factors that appear positive for benchmark Pharma is UBS’s GDP forecasts, according to which PMIs should fall. Pharma is the most negatively correlated sector with PMIs, points out UBS. Also, it is discounting a PMI of 60, where its underperformance is consistent with a European GDP growth rate of +3%.</p><p>Also, notes UBS, Pharma typically underperforms when credit spreads rise, given its http://www.streetinsider.com/Hot+List+Pro/UBS+on+why+it%27s+still+not+ready+to+push+the+buy+button+on+pharma+stocks/25420510.html Sun, 05 Oct 2025 20:00:00 -0400 ABT IHE JNJ http://www.streetinsider.com/Hot+List+Pro/UBS+on+why+it%27s+still+not+ready+to+push+the+buy+button+on+pharma+stocks/25420510.html <p>There are many factors that appear supportive for Pharma heading into Q3. And yet, UBS says it is not yet ready to turn bullish on the sector, though it has highlighted several stocks it has Buy ratings on.</p><p>Among the factors that appear positive for benchmark Pharma is UBS’s GDP forecasts, according to which PMIs should fall. Pharma is the most negatively correlated sector with PMIs, points out UBS. Also, it is discounting a PMI of 60, where its underperformance is consistent with a European GDP growth rate of +3%.</p><p>Also, notes UBS, Pharma typically underperforms when credit spreads rise, given its http://www.streetinsider.com/Hot+List+Pro/UBS+on+why+it%27s+still+not+ready+to+push+the+buy+button+on+pharma+stocks/25420510.html Sun, 05 Oct 2025 20:00:00 -0400 ABT IHE JNJ http://www.streetinsider.com/Hot+List+Pro/UBS+on+why+it%27s+still+not+ready+to+push+the+buy+button+on+pharma+stocks/25420510.html <p>There are many factors that appear supportive for Pharma heading into Q3. And yet, UBS says it is not yet ready to turn bullish on the sector, though it has highlighted several stocks it has Buy ratings on.</p><p>Among the factors that appear positive for benchmark Pharma is UBS’s GDP forecasts, according to which PMIs should fall. Pharma is the most negatively correlated sector with PMIs, points out UBS. Also, it is discounting a PMI of 60, where its underperformance is consistent with a European GDP growth rate of +3%.</p><p>Also, notes UBS, Pharma typically underperforms when credit spreads rise, given its http://www.streetinsider.com/Hot+List+Pro/UBS+on+why+it%27s+still+not+ready+to+push+the+buy+button+on+pharma+stocks/25420510.html Sun, 05 Oct 2025 20:00:00 -0400 ABT IHE JNJ http://www.streetinsider.com/Options/Ishares+U.s.+Pharmaceuticals+Etf+%28IHE%29+30-day+option+implied+volatility+as+share+price+up/25408812.html <p>Ishares U.s. Pharmaceuticals Etf (NYSE: IHE) 30-day option implied volatility is at 15; compared to its 52-week range of 13 to 40 as share price up.</p> http://www.streetinsider.com/Options/Ishares+U.s.+Pharmaceuticals+Etf+%28IHE%29+30-day+option+implied+volatility+as+share+price+up/25408812.html Thu, 02 Oct 2025 04:46:19 -0400 IHE http://www.streetinsider.com/Options/Ishares+U.s.+Pharmaceuticals+Etf+%28IHE%29+30-day+option+implied+volatility+low%2C+share+price+up+1.8%25/25404526.html <p>Ishares U.s. Pharmaceuticals Etf (NYSE: IHE) 30-day option implied volatility is at 16; compared to its 52-week range of 13 to 40 as share price up 1.8%.</p> http://www.streetinsider.com/Options/Ishares+U.s.+Pharmaceuticals+Etf+%28IHE%29+30-day+option+implied+volatility+low%2C+share+price+up+1.8%25/25404526.html Wed, 01 Oct 2025 10:19:38 -0400 IHE http://www.streetinsider.com/Hot+List/Why+public+perception+matters+so+much+for+biotech+valuations/25278645.html <p>In a note on the U.S. Biotechnology sector, Bernstein SocGen analysts addressed the deteriorating reputation of the drug industry, the differential reputational profile of biotech versus pharma, and how the histories of the two industries influence their public perception today.</p><p>“The drug industry’s reputation has steadily deteriorated over the past two decades, and appears unlikely to be reversed by a single event or breakthrough,” say firm analysts. Even the major scientific breakthroughs and positive contributions to public health during the COVID pandemic have not been able to improve perceptions durably.</p><p>The biotech industry is perceived more favourably than the pharma industry, with http://www.streetinsider.com/Hot+List/Why+public+perception+matters+so+much+for+biotech+valuations/25278645.html Sat, 30 Aug 2025 16:00:00 -0400 ALNY BEAM BHVN BMRN IHE NTLA REGN RNA http://www.streetinsider.com/Hot+List/Why+public+perception+matters+so+much+for+biotech+valuations/25278645.html <p>In a note on the U.S. Biotechnology sector, Bernstein SocGen analysts addressed the deteriorating reputation of the drug industry, the differential reputational profile of biotech versus pharma, and how the histories of the two industries influence their public perception today.</p><p>“The drug industry’s reputation has steadily deteriorated over the past two decades, and appears unlikely to be reversed by a single event or breakthrough,” say firm analysts. Even the major scientific breakthroughs and positive contributions to public health during the COVID pandemic have not been able to improve perceptions durably.</p><p>The biotech industry is perceived more favourably than the pharma industry, with http://www.streetinsider.com/Hot+List/Why+public+perception+matters+so+much+for+biotech+valuations/25278645.html Sat, 30 Aug 2025 16:00:00 -0400 ALNY BEAM BHVN BMRN IHE NTLA REGN RNA http://www.streetinsider.com/Hot+List/Why+public+perception+matters+so+much+for+biotech+valuations/25278645.html <p>In a note on the U.S. Biotechnology sector, Bernstein SocGen analysts addressed the deteriorating reputation of the drug industry, the differential reputational profile of biotech versus pharma, and how the histories of the two industries influence their public perception today.</p><p>“The drug industry’s reputation has steadily deteriorated over the past two decades, and appears unlikely to be reversed by a single event or breakthrough,” say firm analysts. Even the major scientific breakthroughs and positive contributions to public health during the COVID pandemic have not been able to improve perceptions durably.</p><p>The biotech industry is perceived more favourably than the pharma industry, with http://www.streetinsider.com/Hot+List/Why+public+perception+matters+so+much+for+biotech+valuations/25278645.html Sat, 30 Aug 2025 16:00:00 -0400 ALNY BEAM BHVN BMRN IHE NTLA REGN RNA http://www.streetinsider.com/Hot+List/Why+public+perception+matters+so+much+for+biotech+valuations/25278645.html <p>In a note on the U.S. Biotechnology sector, Bernstein SocGen analysts addressed the deteriorating reputation of the drug industry, the differential reputational profile of biotech versus pharma, and how the histories of the two industries influence their public perception today.</p><p>“The drug industry’s reputation has steadily deteriorated over the past two decades, and appears unlikely to be reversed by a single event or breakthrough,” say firm analysts. Even the major scientific breakthroughs and positive contributions to public health during the COVID pandemic have not been able to improve perceptions durably.</p><p>The biotech industry is perceived more favourably than the pharma industry, with http://www.streetinsider.com/Hot+List/Why+public+perception+matters+so+much+for+biotech+valuations/25278645.html Sat, 30 Aug 2025 16:00:00 -0400 ALNY BEAM BHVN BMRN IHE NTLA REGN RNA http://www.streetinsider.com/Hot+List/Why+public+perception+matters+so+much+for+biotech+valuations/25278645.html <p>In a note on the U.S. Biotechnology sector, Bernstein SocGen analysts addressed the deteriorating reputation of the drug industry, the differential reputational profile of biotech versus pharma, and how the histories of the two industries influence their public perception today.</p><p>“The drug industry’s reputation has steadily deteriorated over the past two decades, and appears unlikely to be reversed by a single event or breakthrough,” say firm analysts. Even the major scientific breakthroughs and positive contributions to public health during the COVID pandemic have not been able to improve perceptions durably.</p><p>The biotech industry is perceived more favourably than the pharma industry, with http://www.streetinsider.com/Hot+List/Why+public+perception+matters+so+much+for+biotech+valuations/25278645.html Sat, 30 Aug 2025 16:00:00 -0400 ALNY BEAM BHVN BMRN IHE NTLA REGN RNA http://www.streetinsider.com/Hot+List/Why+public+perception+matters+so+much+for+biotech+valuations/25278645.html <p>In a note on the U.S. Biotechnology sector, Bernstein SocGen analysts addressed the deteriorating reputation of the drug industry, the differential reputational profile of biotech versus pharma, and how the histories of the two industries influence their public perception today.</p><p>“The drug industry’s reputation has steadily deteriorated over the past two decades, and appears unlikely to be reversed by a single event or breakthrough,” say firm analysts. Even the major scientific breakthroughs and positive contributions to public health during the COVID pandemic have not been able to improve perceptions durably.</p><p>The biotech industry is perceived more favourably than the pharma industry, with http://www.streetinsider.com/Hot+List/Why+public+perception+matters+so+much+for+biotech+valuations/25278645.html Sat, 30 Aug 2025 16:00:00 -0400 ALNY BEAM BHVN BMRN IHE NTLA REGN RNA http://www.streetinsider.com/Hot+List/Why+public+perception+matters+so+much+for+biotech+valuations/25278645.html <p>In a note on the U.S. Biotechnology sector, Bernstein SocGen analysts addressed the deteriorating reputation of the drug industry, the differential reputational profile of biotech versus pharma, and how the histories of the two industries influence their public perception today.</p><p>“The drug industry’s reputation has steadily deteriorated over the past two decades, and appears unlikely to be reversed by a single event or breakthrough,” say firm analysts. Even the major scientific breakthroughs and positive contributions to public health during the COVID pandemic have not been able to improve perceptions durably.</p><p>The biotech industry is perceived more favourably than the pharma industry, with http://www.streetinsider.com/Hot+List/Why+public+perception+matters+so+much+for+biotech+valuations/25278645.html Sat, 30 Aug 2025 16:00:00 -0400 ALNY BEAM BHVN BMRN IHE NTLA REGN RNA http://www.streetinsider.com/Hot+List/Why+public+perception+matters+so+much+for+biotech+valuations/25278645.html <p>In a note on the U.S. Biotechnology sector, Bernstein SocGen analysts addressed the deteriorating reputation of the drug industry, the differential reputational profile of biotech versus pharma, and how the histories of the two industries influence their public perception today.</p><p>“The drug industry’s reputation has steadily deteriorated over the past two decades, and appears unlikely to be reversed by a single event or breakthrough,” say firm analysts. Even the major scientific breakthroughs and positive contributions to public health during the COVID pandemic have not been able to improve perceptions durably.</p><p>The biotech industry is perceived more favourably than the pharma industry, with http://www.streetinsider.com/Hot+List/Why+public+perception+matters+so+much+for+biotech+valuations/25278645.html Sat, 30 Aug 2025 16:00:00 -0400 ALNY BEAM BHVN BMRN IHE NTLA REGN RNA http://www.streetinsider.com/Hot+List+Pro/Why+public+perception+matters+so+much+for+biotech+valuations/25278645.html <p>In a note on the U.S. Biotechnology sector, Bernstein SocGen analysts addressed the deteriorating reputation of the drug industry, the differential reputational profile of biotech versus pharma, and how the histories of the two industries influence their public perception today.</p><p>“The drug industry’s reputation has steadily deteriorated over the past two decades, and appears unlikely to be reversed by a single event or breakthrough,” say firm analysts. Even the major scientific breakthroughs and positive contributions to public health during the COVID pandemic have not been able to improve perceptions durably.</p><p>The biotech industry is perceived more favourably than the pharma industry, with http://www.streetinsider.com/Hot+List+Pro/Why+public+perception+matters+so+much+for+biotech+valuations/25278645.html Sat, 30 Aug 2025 16:00:00 -0400 ALNY BEAM BHVN BMRN IHE NTLA REGN RNA http://www.streetinsider.com/Hot+List+Pro/Why+public+perception+matters+so+much+for+biotech+valuations/25278645.html <p>In a note on the U.S. Biotechnology sector, Bernstein SocGen analysts addressed the deteriorating reputation of the drug industry, the differential reputational profile of biotech versus pharma, and how the histories of the two industries influence their public perception today.</p><p>“The drug industry’s reputation has steadily deteriorated over the past two decades, and appears unlikely to be reversed by a single event or breakthrough,” say firm analysts. Even the major scientific breakthroughs and positive contributions to public health during the COVID pandemic have not been able to improve perceptions durably.</p><p>The biotech industry is perceived more favourably than the pharma industry, with http://www.streetinsider.com/Hot+List+Pro/Why+public+perception+matters+so+much+for+biotech+valuations/25278645.html Sat, 30 Aug 2025 16:00:00 -0400 ALNY BEAM BHVN BMRN IHE NTLA REGN RNA http://www.streetinsider.com/Hot+List+Pro/Why+public+perception+matters+so+much+for+biotech+valuations/25278645.html <p>In a note on the U.S. Biotechnology sector, Bernstein SocGen analysts addressed the deteriorating reputation of the drug industry, the differential reputational profile of biotech versus pharma, and how the histories of the two industries influence their public perception today.</p><p>“The drug industry’s reputation has steadily deteriorated over the past two decades, and appears unlikely to be reversed by a single event or breakthrough,” say firm analysts. Even the major scientific breakthroughs and positive contributions to public health during the COVID pandemic have not been able to improve perceptions durably.</p><p>The biotech industry is perceived more favourably than the pharma industry, with http://www.streetinsider.com/Hot+List+Pro/Why+public+perception+matters+so+much+for+biotech+valuations/25278645.html Sat, 30 Aug 2025 16:00:00 -0400 ALNY BEAM BHVN BMRN IHE NTLA REGN RNA http://www.streetinsider.com/Hot+List+Pro/Why+public+perception+matters+so+much+for+biotech+valuations/25278645.html <p>In a note on the U.S. Biotechnology sector, Bernstein SocGen analysts addressed the deteriorating reputation of the drug industry, the differential reputational profile of biotech versus pharma, and how the histories of the two industries influence their public perception today.</p><p>“The drug industry’s reputation has steadily deteriorated over the past two decades, and appears unlikely to be reversed by a single event or breakthrough,” say firm analysts. Even the major scientific breakthroughs and positive contributions to public health during the COVID pandemic have not been able to improve perceptions durably.</p><p>The biotech industry is perceived more favourably than the pharma industry, with http://www.streetinsider.com/Hot+List+Pro/Why+public+perception+matters+so+much+for+biotech+valuations/25278645.html Sat, 30 Aug 2025 16:00:00 -0400 ALNY BEAM BHVN BMRN IHE NTLA REGN RNA http://www.streetinsider.com/Hot+List+Pro/Why+public+perception+matters+so+much+for+biotech+valuations/25278645.html <p>In a note on the U.S. Biotechnology sector, Bernstein SocGen analysts addressed the deteriorating reputation of the drug industry, the differential reputational profile of biotech versus pharma, and how the histories of the two industries influence their public perception today.</p><p>“The drug industry’s reputation has steadily deteriorated over the past two decades, and appears unlikely to be reversed by a single event or breakthrough,” say firm analysts. Even the major scientific breakthroughs and positive contributions to public health during the COVID pandemic have not been able to improve perceptions durably.</p><p>The biotech industry is perceived more favourably than the pharma industry, with http://www.streetinsider.com/Hot+List+Pro/Why+public+perception+matters+so+much+for+biotech+valuations/25278645.html Sat, 30 Aug 2025 16:00:00 -0400 ALNY BEAM BHVN BMRN IHE NTLA REGN RNA http://www.streetinsider.com/Hot+List+Pro/Why+public+perception+matters+so+much+for+biotech+valuations/25278645.html <p>In a note on the U.S. Biotechnology sector, Bernstein SocGen analysts addressed the deteriorating reputation of the drug industry, the differential reputational profile of biotech versus pharma, and how the histories of the two industries influence their public perception today.</p><p>“The drug industry’s reputation has steadily deteriorated over the past two decades, and appears unlikely to be reversed by a single event or breakthrough,” say firm analysts. Even the major scientific breakthroughs and positive contributions to public health during the COVID pandemic have not been able to improve perceptions durably.</p><p>The biotech industry is perceived more favourably than the pharma industry, with http://www.streetinsider.com/Hot+List+Pro/Why+public+perception+matters+so+much+for+biotech+valuations/25278645.html Sat, 30 Aug 2025 16:00:00 -0400 ALNY BEAM BHVN BMRN IHE NTLA REGN RNA http://www.streetinsider.com/Hot+List+Pro/Why+public+perception+matters+so+much+for+biotech+valuations/25278645.html <p>In a note on the U.S. Biotechnology sector, Bernstein SocGen analysts addressed the deteriorating reputation of the drug industry, the differential reputational profile of biotech versus pharma, and how the histories of the two industries influence their public perception today.</p><p>“The drug industry’s reputation has steadily deteriorated over the past two decades, and appears unlikely to be reversed by a single event or breakthrough,” say firm analysts. Even the major scientific breakthroughs and positive contributions to public health during the COVID pandemic have not been able to improve perceptions durably.</p><p>The biotech industry is perceived more favourably than the pharma industry, with http://www.streetinsider.com/Hot+List+Pro/Why+public+perception+matters+so+much+for+biotech+valuations/25278645.html Sat, 30 Aug 2025 16:00:00 -0400 ALNY BEAM BHVN BMRN IHE NTLA REGN RNA http://www.streetinsider.com/Hot+List+Pro/Why+public+perception+matters+so+much+for+biotech+valuations/25278645.html <p>In a note on the U.S. Biotechnology sector, Bernstein SocGen analysts addressed the deteriorating reputation of the drug industry, the differential reputational profile of biotech versus pharma, and how the histories of the two industries influence their public perception today.</p><p>“The drug industry’s reputation has steadily deteriorated over the past two decades, and appears unlikely to be reversed by a single event or breakthrough,” say firm analysts. Even the major scientific breakthroughs and positive contributions to public health during the COVID pandemic have not been able to improve perceptions durably.</p><p>The biotech industry is perceived more favourably than the pharma industry, with http://www.streetinsider.com/Hot+List+Pro/Why+public+perception+matters+so+much+for+biotech+valuations/25278645.html Sat, 30 Aug 2025 16:00:00 -0400 ALNY BEAM BHVN BMRN IHE NTLA REGN RNA http://www.streetinsider.com/Investing/Pharma+stocks+up+on+US+tariff+exemptions+but+analyst+flags+a+%2446B+import+cost+risk/24594868.html <p>Investing.com -- Pharmaceutical stocks saw brief relief Thursday after U.S. President Donald Trump left drug products off the list of newly announced tariffs. However, industry leaders and analysts cautioned that the sector is not in the clear, as targeted levies may still be on the horizon.</p> <p>Trump’s latest tariff package included a 10% duty on most U.S. imports and significantly higher rates on goods from various trading partners. Pharmaceuticals were among a handful of categories granted a temporary exemption—an outcome that favored key exporters like India, Japan, and Ireland.</p> <p>U.S. drugmakers traded relatively flat in premarket trading, with Amgen (NASDAQ:AMGN) and Johnson&amp;Johnson http://www.streetinsider.com/Investing/Pharma+stocks+up+on+US+tariff+exemptions+but+analyst+flags+a+%2446B+import+cost+risk/24594868.html Thu, 03 Apr 2025 08:07:39 -0400 ABBV AMGN AZN BIIB IHE JAZZ JNJ MRK NVO PFE REGN XPH